Loading stock data…
Journey Medical Corporation (DERM)
$6.79+0.17 (+2.57%)
After Hours$6.79+0.00 (+0.00%)· Last close Jun 29
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Journey Medical Corporation in the Healthcare sector is trading at $6.79 with a market capitalization of $167M. Wall Street consensus targets $13.50 (4 analysts), implying a +98.8% move over the next 12 months. The stock is currently 29% below its 52-week high of $9.55, remaining 4.5% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +98.8% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.96M↓ | $16.08M↓ | $17.63M↑ | $15.01M↑ | $13.14M |
| Gross Profit | $9.74M↓ | $10.64M↓ | $11.88M↑ | $10.07M↑ | $8.35M |
| Operating Income | -$1.49M↓ | -$443,000↑ | -$1.53M↑ | -$2.88M↑ | -$3.32M |
| Net Income | -$2.23M↓ | -$1.25M↑ | -$2.31M↑ | -$3.80M↑ | -$4.07M |
Peer Comparison
JNJUNHPFE
Fundamentals
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed produc...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$166.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.03
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.10%
Volume
Today's trading volume
281,969
Recent News
Journey Medical (DERM) Stock Draws Fresh Price Target Split After Fortress Valuation Changes
Journey Medical is back in focus as analysts revisit their price targets in light of fresh information around its role inside Fortress Biotech and the implied value of its shares and cash position. Recent commentary ties these price target moves directly to how Journey Medical contributes to Fortress's asset base, while core modeling inputs such as fair value at $13.50, a 7.108% discount rate, 46.87% revenue growth, 25.61% net profit margin, and a 10.43x future P/E are held steady. Ahead, you...
How The Journey Medical (DERM) Investment Narrative Is Evolving With An Unchanged Valuation Target
Journey Medical’s latest analyst update keeps the existing price target unchanged, signaling no shift in published expectations around the stock’s valuation level for now. Even with no new commentary from analysts, this steady price target still carries information about how the story currently stands in the market. Looking ahead, you will see how to track future updates so you can stay aligned with the evolving narrative around Journey Medical. Analyst Price Targets don't always capture the...
Journey Medical Corporation Q1 2026 Earnings Call Summary
Moby summary of Journey Medical Corporation's Q1 2026 earnings call
Journey Medical Corp (DERM) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
Journey Medical Corp (DERM) reports strong revenue growth and strategic partnerships, despite facing margin pressures and reimbursement challenges.
Here's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings
The headline numbers for Journey Medical (DERM) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.